Regeneron Pharmaceuticals (NASDAQ:REGN) Stock: Insider Andrew Murphy Sells 4,147 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insider Andrew Murphy sold 4,147 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. This trade represents a 7.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Stock Up 2.3%

Shares of NASDAQ:REGN traded up $17.98 during midday trading on Thursday, reaching $796.34. The company’s stock had a trading volume of 798,814 shares, compared to its average volume of 822,409. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $791.11 and a 200-day moving average of $720.89. The firm has a market capitalization of $81.99 billion, a P/E ratio of 19.68, a PEG ratio of 1.30 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a 12-month low of $564.00 and a 12-month high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same period last year, the company posted $12.81 EPS. Regeneron Pharmaceuticals’s revenue was up 16.7% on a year-over-year basis. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 47.93 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a dividend of $0.94 per share. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Analyst Ratings Changes

A number of analysts have recently commented on REGN shares. Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. Guggenheim upped their price target on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Evercore raised their price objective on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research note on Thursday, July 9th. Finally, Leerink Partners lifted their price objective on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $834.24.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Arjuna Capital grew its holdings in Regeneron Pharmaceuticals by 3.2% during the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after buying an additional 14 shares in the last quarter. Boyd Watterson Asset Management LLC OH lifted its holdings in shares of Regeneron Pharmaceuticals by 1.4% in the first quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 15 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 1.8% in the first quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock worth $645,000 after buying an additional 15 shares in the last quarter. Aaron Wealth Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 1.5% during the first quarter. Aaron Wealth Advisors LLC now owns 1,102 shares of the biopharmaceutical company’s stock worth $851,000 after acquiring an additional 16 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in Regeneron Pharmaceuticals by 30.2% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 69 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 16 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.